D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $12 from $24 and keeps a Buy rating on the shares after the company announced it is discontinuing the development of CT-0525 as part of a “strategic reprioritization. The firm reduced HERII cancers from its projections.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics announces restructuring, 34% workforce reduction
- Carisma Therapeutics Restructures Amid Strategic Refocus
- Carisma Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
- Carisma Therapeutics reports data from its CAR-M therapy
- Carisma Therapeutics reports Q3 EPS (31c), consensus (26c)